Multidisciplinary Management of Severe Taxane-Induced Nail Toxicity in a Breast Cancer Patient Authors: Natalia Sauer, Marta Kowalczuk, Adrian Arkada, Jacek Calik Published: 2026 ABSTRACT AbstractIntroductionTaxane-induced nail toxicity (TINT) is a relatively common but often underreported adverse effect of docetaxel-based chemotherapy that may significantly impair quality of life and functional status. Severe cases can require structured supportive care involving multiple clinical disciplines. We present a case of high-grade TINT in a patient with breast cancer successfully managed with a multidisciplinary supportive approach.Case PresentationA 70-year-old woman with HER2-positive breast cancer received neoadjuvant TCH chemotherapy (docetaxel, cyclophosphamide, trastuzumab), followed by surgery and adjuvant trastuzumab emtansine. Nail toxicity developed after the second cycle of docetaxel and progressed to subungual hemorrhages, onycholysis, and marked onychodystrophy associated with pain and functional limitation. The patient underwent podiatric treatment including mechanical nail debridement and topical collagen-based serum therapy. Supportive pharmacologic management, including selective COX-2 inhibitors, was also introduced.ResultsGradual epithelial healing and nail regrowth were observed over a six-month follow-up period. Pain and functional impairment improved, and systemic oncologic therapy was continued without interruption. No recurrence of severe nail complications was noted during subsequent treatment.ConclusionThis case illustrates that severe taxane-induced nail toxicity may be effectively controlled with coordinated multidisciplinary supportive care. Early podiatric intervention combined with pharmacologic symptom management may help maintain treatment continuity and improve patient comfort during taxane-based chemotherapy.Keywords: nails, taxane-induced nail toxicity, breast cancer, ADR Introduction HER2-positive breast cancer is a biologically aggressive subtype whose prognosis has significantly improved with the introduction of targeted therapies into clinical practice.1 In this patient population, chemotherapy combined with trastuzumab and other HER2-targeted agents constitutes the backbone of both neoadjuvant and adjuvant treatment strategies. Among cytotoxic agents, taxanes–particularly docetaxel—represent indispensable components of these regimens due to their high antitumor efficacy. In addition, docetaxel is widely used not only in breast cancer but also in several other solid tumors, including non-small cell lung, prostate, gastric, head and neck, and ovarian cancers. Despite its substantial clinical utility, docetaxel therapy is associated with multiple adverse events that may affect treatment tolerability and patient quality of life. Docetaxel, a member of the taxane family, is a cornerstone of systemic breast cancer therapy and demonstrates significant efficacy in both early and advanced disease settings.2 Its mechanism of action involves stabilizing microtubules, thereby disrupting mitotic spindle function and inducing apoptosis in rapidly proliferating cancer cells.3 Among its dermatologic adverse effects, nail toxicity represents a clinically relevant yet still underrecognized complication that may substantially affect treatment adherence and functional outcomes. Taxane-induced nail toxicity (TINT) represents a clinically significant adverse effect of docetaxel-based chemotherapy, with reported incidence ranging from 0% to 44% depending on treatment regimen and assessment methodology.4 In large cohorts, approximately 34.9% of patients receiving docetaxel and 43.7% of those treated with paclitaxel develop clinically relevant nail alterations, including severe manifestations requiring medical intervention in up to 14.7% of affected individuals.5,6 Clinical manifestations of TINT include onycholysis, subungual hemorrhages, Beau’s lines, nail plate fragility, and periungual inflammation, which may be associated with pain, functional impairment, and an increased risk of secondary infection.7–14 Although the pathophysiology of these changes remains incompletely understood, several mechanisms have been proposed, including direct cytotoxic injury to the nail matrix, chemotherapy-induced microvascular damage, neurogenic factors, and inflammatory processes contributing to impaired nail growth and structural instability.9,15–19 Importantly, severe nail toxicity may extend beyond cosmetic changes and represent a meaningful supportive-care challenge. Patients frequently report pain and limitations in daily activities such as writing, typing, or grasping objects, and more than 40% of individuals with significant nail toxicity consider dose reductions or temporary treatment interruptions. In complicated cases involving secondary infection, 10–20% of patients require systemic antibiotic therapy, further affecting treatment continuity.4,5,20 Although preventive strategies such as cryotherapy using frozen gloves and socks during taxane infusion have demonstrated efficacy in reducing nail toxicity incidence (from 51% to 11%), therapeutic options for established high-grade toxicity remain limited and inconsistently supported by evidence.21 Similarly, topical supportive interventions—including hydrating preparations and polyphenol-rich balms—have shown variable benefit across studies.22 In this context, structured multidisciplinary supportive care may play an important role in managing severe nail toxicity while maintaining oncologic treatment continuity. However, the role of podiatric intervention remains insufficiently represented in the supportive oncology literature. The present case illustrates a severe presentation of taxane-induced nail toxicity requiring coordinated management involving an oncologist, pharmacist, and podiatrist, and highlights the potential clinical value of integrated supportive strategies in preserving patient function and enabling continuation of systemic anticancer therapy. Case Description A 70-year-old female patient was diagnosed with right breast cancer, initially classified as cT2N0M0, with a clinical stage of CS II. Over time, the disease progressed to CS IV, with bone metastases detected. The patient underwent a core needle biopsy on July 7, 2023, confirming invasive ductal carcinoma, hormone receptor-positive (ER 90–100%, PR 20–30%), HER2-positive, and Ki67 proliferation index between 20–30%. Neoadjuvant chemotherapy was initiated on November 8, 2023, and completed on February 21, 2024, using the TCH regimen (docetaxel, cyclophosphamide, trastuzumab). During the chemotherapy course, the patient developed taxane-induced nail toxicity (TINT), which became apparent after the second cycle of docetaxel. Initial manifestations included nail plate fragility, onycholysis, and periungual erythema, progressively worsening with subsequent treatment cycles. By the end of chemotherapy in February 2024, the patient exhibited subungual hemorrhages, Beau’s lines, and severe onychodystrophy affecting multiple fingernails, leading to significant discomfort and functional impairment. The changes were most pronounced in the fingernails, while toenails remained unaffected. Subsequently, the patient underwent breast-conserving surgery with sentinel lymph node biopsy on March 13, 2024, utilizing the ICG/Sentimag method. The histopathological assessment revealed ypT1bN0(sn)MX, LVI0, PNI0, and R0 resection status. Hormonal receptor status was PR 60–70% and ER 90–100%, while HER2 expression varied between 1+ and 2+, with Ki67 decreasing to 1–10%. Postoperatively, the patient received adjuvant radiotherapy and targeted therapy with trastuzumab emtansine (Kadcyla) for residual disease, which commenced on May 14, 2024, and was discontinued on August 14, 2024, after five cycles. Disease progression was confirmed by PET-CT on October 15, 2024, revealing disseminated bone metastases. A subsequent biopsy of the bone lesion performed on November 19, 2024, indicated dedifferentiation to a luminal B HER2-negative subtype, with definitive loss of HER2 receptor expression. The clinical course was characterized by an atypical disease trajectory for this biological subtype. The patient developed a left-sided rib fracture near the scapula, with associated vascular injury leading to bleeding and anemia. Due to disease progression, first-line palliative therapy with ribociclib (Kisqali) and an aromatase inhibitor was initiated on December 30, 2024. Concurrently, she commenced zoledronic acid therapy on January 14, 2025. Genetic testing for recurrent mutations in BRCA1, CHEK2, and PALB2 was negative. The patient had a medical history significant for hypothyroidism (status post partial thyroidectomy in 2002) and hypertension, managed with Euthyrox 75 mcg and Vivace. She denied any history of smoking or alcohol consumption. A maternal history of breast cancer at the age of 83 was reported. Oncological imaging included mammography on May 26, 2023, which identified a cluster of microcalcifications measuring 13 mm in the upper outer quadrant of the right breast, classified as BIRADS 0. A breast ultrasound on July 3, 2023, revealed a 20-mm hypoechoic lesion with central microcalcifications and minor peritumoral lymphatic swelling, classified as BIRADS 5. Histopathology from the core biopsy confirmed invasive ductal carcinoma, NHG 2 (3+3+1), with HER2 amplification via FISH. A follow-up PET-CT on October 15, 2024, indicated disease progression with multiple bone metastases, an elevated CA 15–3 marker, and a pathological fracture of the left hip joint. In light of the findings, the patient underwent an open biopsy of the iliac crest on November 19, 2024, confirming metastasis of HER2-negative invasive ductal carcinoma. Immunohistochemical analysis demonstrated ER positivity (80–90%), PR positivity (10–20%), and HER2 negativity (1+). Given the change in tumor biology, systemic therapy was adjusted to ribociclib with an aromatase inhibitor, with the first cycle initiated on December 30, 2024. The second cycle was commenced on February 6, 2025. Bisphosphonate therapy with zoledronic acid was continued to manage bone metastases. Management of Taxane-Induced Nail Toxicity The patient underwent a structured podiatric intervention for taxane-induced nail toxicity, employing a mechanical debridement approach (Figure 1). Non-adherent nail plate structures were selectively milled using a high-precision burr, ensuring the preservation of healthy tissue. The nail bed was subsequently cleaned at lower rotational speeds to minimize trauma while effectively removing residual keratinized debris. Throughout the procedure, cooling agents and compressed air were applied intermittently to enhance patient comfort, eliminating the need for local or systemic analgesia. Post-procedural care included the application of TC 16 serum (15% fish collagen and 1% natural tea tree oil (Melaleuca alternifolia)), facilitating epithelialization and promoting controlled nail regrowth. During follow-up visits, mechanical debridement was performed as needed, maintaining optimal conditions for progressive nail recovery. This interdisciplinary approach, integrating clinical oncology, podiatry, and pharmaceutical support, enabled effective toxicity management and restored nail integrity over time. Progressive improvement of taxane-induced nail toxicity during multidisciplinary supportive management. (A) Initial presentation of severe taxane-induced nail toxicity with subungual hemorrhages, onycholysis, and nail plate discoloration (March 2024). (B) Early post-procedural appearance following podiatric mechanical debridement of damaged nail plates (March 2024). (C) Intermediate healing stage showing epithelialization and early nail regrowth during continued supportive care, including topical TC-16 serum and regular mechanical nail maintenance (June 2024). (D) Advanced healing stage with substantial nail regrowth and resolution of previous abnormalities during ongoing multidisciplinary supportive management (September 2024). Discussion This case highlights a severe presentation of taxane-induced nail toxicity (TINT) in a patient with advanced breast cancer receiving docetaxel-based chemotherapy. The patient developed progressive nail changes – including brittle nails, onycholysis, periungual inflammation, subungual haemorrhages – that caused significant pain and functional impairment. These findings underscore both the clinical impact of TINT and the importance of a coordinated multidisciplinary management. Nail toxicity is a well-recognised complication of taxane chemotherapy. The reported incidence of taxane-induced nail changes varies widely, in part due to under-reporting and differences in chemotherapy regimens.4,5 A 2015 meta-analysis found nail changes in approximately 34–44% of patients on docetaxel or paclitaxel.23 Some series have observed any degree of nail change in over 80% of patients after a few cycles,24 whereas severe grade 3 toxicity is less common.6 Fingernails and toenails are both affected, often after several chemotherapy cycles as cumulative dose increases.25 Clinically, taxane-induced nail toxicity encompasses a broad spectrum from mild cosmetic alterations to debilitating injury. Common manifestations include discolouration, Beau’s lines, onychomadesis, subungual haemorrhages, and sterile or suppurative paronychia.7,14,26 More severe presentations include painful onycholysis and formation of subungual hematomas or abscesses.9,14 In our patient, virtually all fingernails were affected, indicating a high-grade toxicity. Notably, these changes not only caused local pain but also interfered with daily activities, emphasizing that even peripheral toxicities can significantly impact a patient’s functional status.20,27 Taxane-induced nail toxicity (TINT) is considered a multifactorial complication. A principal mechanism involves the direct cytotoxic effect of taxanes on rapidly proliferating keratinocytes within the nail matrix and nail bed.15,16 Neuroinflammatory mechanisms may also contribute. Wasner et al described a patient with unilateral brachial plexus paralysis who developed onycholysis in all nails except those of the denervated hand, suggesting that intact peripheral nerve function may be required for the full expression of TINT.17 In addition, chemotherapy-induced microvascular injury, oxidative stress, and treatment-related immunosuppression are believed to further exacerbate nail pathology.18,19 Diagnosis of TINT is primarily clinical. Early nail changes may progress if not promptly recognized and managed.5 Severity is typically graded using the Common Terminology Criteria for Adverse Events (CTCAE) classification system.6 However, dermatologic toxicities remain inconsistently reported in clinical practice, and clinician-reported rates often underestimate the burden described in patient-reported outcome measures.14 In most cases, nail abnormalities gradually resolve within weeks to months after completion of chemotherapy.7 Management of TINT is inherently multidisciplinary and includes both preventive and therapeutic strategies. Preventive approaches such as limb cryotherapy during taxane infusion reduce drug exposure to the nail apparatus and have been shown to significantly decrease the incidence of nail toxicity.21,28 Additional supportive measures, including hydrating nail preparations and polyphenol-rich topical formulations, have been investigated, although the available evidence remains limited.14,22 Treatment of established toxicity may involve topical antiseptics, antibiotics, corticosteroids, mechanical nail debridement, and, in more severe cases, systemic antibiotics or anti-inflammatory agents such as selective COX-2 inhibitors.6,7,22 In the present case, structured podiatric care combined with COX-2 inhibitor therapy was associated with pain reduction and progressive nail regrowth during continued oncologic treatment. Beyond physical symptoms, TINT may substantially affect psychosocial well-being. Patients frequently report embarrassment, altered body image, and functional limitations affecting everyday activities.20,29 These factors may influence treatment adherence, with some patients considering dose reductions or temporary treatment interruptions.4 Therefore, appropriate supportive care and clear communication remain essential components of maintaining treatment continuity and patient confidence. This case highlights the practical value of coordinated multidisciplinary supportive care in managing severe treatment-related nail toxicity. Effective management required close collaboration between oncology, podiatry, and pharmacologic supportive care, reflecting current recommendations emphasizing patient-centered and toxicity-aware cancer treatment strategies.30,31 Furthermore, in advanced breast cancer, evolving tumour biology necessitates ongoing reassessment and individualized systemic therapy, as illustrated by the transition from HER2-targeted therapy to endocrine treatment following disease progression in the present patient.32–34 Although conclusions from a single case must be interpreted cautiously, this report demonstrates that even severe TINT may be successfully managed with structured supportive intervention, allowing continuation of systemic anticancer therapy while preserving patient comfort and functional status. Limitations This report has several limitations that should be acknowledged. First, as a single-patient observation, the findings cannot be generalized to the broader population of patients receiving taxane-based chemotherapy. Second, objective dermatologic grading using standardized longitudinal CTCAE scoring at multiple time points was limited, and assessment relied primarily on clinical evaluation and functional outcomes. Third, the multidisciplinary intervention combined several supportive strategies simultaneously, which precludes precise attribution of the observed improvement to any single therapeutic component. Finally, preventive strategies such as limb cryotherapy were not applied during docetaxel administration, which limits comparison between prophylactic and therapeutic management approaches. Further prospective studies are warranted to better define optimal management pathways for severe taxane-induced nail toxicity. Conclusions Severe taxane-induced nail toxicity represents a clinically relevant but frequently underrecognized complication of systemic anticancer therapy that may substantially impair patient comfort, functional capacity, and quality of life. As illustrated in this case, early recognition and structured supportive management may help control symptoms and support continuation of oncologic treatment without interruption. This report highlights the potential role of coordinated multidisciplinary care—including oncologic supervision, podiatric intervention, and symptom-directed pharmacologic support—in the management of high-grade nail toxicity during taxane-based chemotherapy. Although conclusions regarding treatment effectiveness cannot be drawn from a single clinical observation, this case provides a practical example of how integrated supportive-care strategies may contribute to maintaining treatment adherence and improving patient well-being. Greater awareness of taxane-induced nail toxicity and timely referral for supportive interventions may facilitate earlier management of symptoms and encourage broader incorporation of multidisciplinary approaches into routine supportive oncology practice. Funding Statement This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data Source Statement All clinical data were derived from the patient’s medical records and routine oncological care at the University Hospital in Wrocław and AArkada Institute of Podiatry. No external databases or unpublished datasets were used. Ethics Approval Ethical approval was not required for this case report, as it describes a single anonymized patient and was conducted in accordance with institutional and international ethical standards. Written informed consent for publication of clinical details and images was obtained from the patient. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no conflicts of interest relevant to the content of this article. References